Literature DB >> 26351277

STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans.

Chrissy M Leopold Wager1, Camaron R Hole1, Karen L Wozniak1, Michal A Olszewski2, Mathias Mueller3, Floyd L Wormley4.   

Abstract

Cryptococcus neoformans, the predominant etiological agent of cryptococcosis, is an opportunistic fungal pathogen that primarily affects AIDS patients and patients undergoing immunosuppressive therapy. In immunocompromised individuals, C. neoformans can lead to life-threatening meningoencephalitis. Studies using a virulent strain of C. neoformans engineered to produce gamma interferon (IFN-γ), denoted H99γ, demonstrated that protection against pulmonary C. neoformans infection is associated with the generation of a T helper 1 (Th1)-type immune response and signal transducer and activator of transcription 1 (STAT1)-mediated classical (M1) macrophage activation. However, the critical mechanism by which M1 macrophages mediate their anti-C. neoformans activity remains unknown. The current studies demonstrate that infection with C. neoformans strain H99γ in mice with macrophage-specific STAT1 ablation resulted in severely increased inflammation of the pulmonary tissue, a dysregulated Th1/Th2-type immune response, increased fungal burden, deficient M1 macrophage activation, and loss of protection. STAT1-deficient macrophages produced significantly less nitric oxide (NO) than STAT1-sufficient macrophages, correlating with an inability to control intracellular cryptococcal proliferation, even in the presence of reactive oxygen species (ROS). Furthermore, macrophages from inducible nitric oxide synthase knockout mice, which had intact ROS production, were deficient in anticryptococcal activity. These data indicate that STAT1 activation within macrophages is required for M1 macrophage activation and anti-C. neoformans activity via the production of NO.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26351277      PMCID: PMC4645398          DOI: 10.1128/IAI.00935-15

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  77 in total

1.  Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulated with interferon-gamma and lipopolysaccharide.

Authors:  K Kawakami; T Zhang; M H Qureshi; A Saito
Journal:  Cell Immunol       Date:  1997-08-25       Impact factor: 4.868

2.  Cryptococcosis in children with AIDS.

Authors:  J Abadi; S Nachman; A B Kressel; L Pirofski
Journal:  Clin Infect Dis       Date:  1999-02       Impact factor: 9.079

3.  Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas.

Authors:  D Goldman; Y Cho; M Zhao; A Casadevall; S C Lee
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

4.  Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung.

Authors:  John J Osterholzer; Rishi Surana; Jami E Milam; Gerald T Montano; Gwo-Hsiao Chen; Joanne Sonstein; Jeffrey L Curtis; Gary B Huffnagle; Galen B Toews; Michal A Olszewski
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

5.  Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS.

Authors:  R J Coker; M Viviani; B G Gazzard; B Du Pont; H D Pohle; S M Murphy; J Atouguia; J L Champalimaud; J R Harris
Journal:  AIDS       Date:  1993-06       Impact factor: 4.177

6.  Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages.

Authors:  Gary M Cox; Thomas S Harrison; Henry C McDade; Carlos P Taborda; Garrett Heinrich; Arturo Casadevall; John R Perfect
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

7.  Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation.

Authors:  Sarah E Hardison; Gina Herrera; Mattie L Young; Camaron R Hole; Karen L Wozniak; Floyd L Wormley
Journal:  J Immunol       Date:  2012-09-14       Impact factor: 5.422

8.  Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions.

Authors:  F Facchetti; W Vermi; S Fiorentini; M Chilosi; A Caruso; M Duse; L D Notarangelo; R Badolato
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

9.  Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-γ.

Authors:  Christine Lang; Anke Hildebrandt; Franziska Brand; Lennart Opitz; Hassan Dihazi; Carsten G K Lüder
Journal:  PLoS Pathog       Date:  2012-01-19       Impact factor: 6.823

10.  Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection.

Authors:  Elisabeth Kernbauer; Verena Maier; Dagmar Stoiber; Birgit Strobl; Christine Schneckenleithner; Veronika Sexl; Ursula Reichart; Boris Reizis; Ulrich Kalinke; Amanda Jamieson; Mathias Müller; Thomas Decker
Journal:  PLoS Pathog       Date:  2012-06-14       Impact factor: 6.823

View more
  39 in total

1.  T Cell-Restricted Notch Signaling Contributes to Pulmonary Th1 and Th2 Immunity during Cryptococcus neoformans Infection.

Authors:  Lori M Neal; Yafeng Qiu; Jooho Chung; Enze Xing; Woosung Cho; Antoni N Malachowski; Ashley R Sandy-Sloat; John J Osterholzer; Ivan Maillard; Michal A Olszewski
Journal:  J Immunol       Date:  2017-06-14       Impact factor: 5.422

2.  The Outcome of the Cryptococcus neoformans-Macrophage Interaction Depends on Phagolysosomal Membrane Integrity.

Authors:  Carlos M De Leon-Rodriguez; Diego C P Rossi; Man Shun Fu; Quigly Dragotakes; Carolina Coelho; Ignacio Guerrero Ros; Benjamin Caballero; Sabrina J Nolan; Arturo Casadevall
Journal:  J Immunol       Date:  2018-06-01       Impact factor: 5.422

Review 3.  Modulators of microglial activation and polarization after intracerebral haemorrhage.

Authors:  Xi Lan; Xiaoning Han; Qian Li; Qing-Wu Yang; Jian Wang
Journal:  Nat Rev Neurol       Date:  2017-05-19       Impact factor: 42.937

Review 4.  Innate host defenses against Cryptococcus neoformans.

Authors:  Camaron Hole; Floyd L Wormley
Journal:  J Microbiol       Date:  2016-02-27       Impact factor: 3.422

5.  Autocrine IL-10 Signaling Promotes Dendritic Cell Type-2 Activation and Persistence of Murine Cryptococcal Lung Infection.

Authors:  Seagal Teitz-Tennenbaum; Steven P Viglianti; Jonathan A Roussey; Stuart M Levitz; Michal A Olszewski; John J Osterholzer
Journal:  J Immunol       Date:  2018-08-10       Impact factor: 5.422

6.  Antifungal Activity of Plasmacytoid Dendritic Cells against Cryptococcus neoformans In Vitro Requires Expression of Dectin-3 (CLEC4D) and Reactive Oxygen Species.

Authors:  Camaron R Hole; Chrissy M Leopold Wager; Andrew S Mendiola; Karen L Wozniak; Althea Campuzano; Xin Lin; Floyd L Wormley
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

7.  Host response to pulmonary fungal infections: A highlight on cell-driven immunity to Cryptococcus species and Aspergillus fumigatus.

Authors:  Orchi Dutta; Jorge A Masso-Silva; Keyi Wang; Amariliz Rivera
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

8.  CD8 T Cells and STAT1 Signaling Are Essential Codeterminants in Protection from Polyomavirus Encephalopathy.

Authors:  Taryn E Mockus; Colleen S Netherby-Winslow; Hannah M Atkins; Matthew D Lauver; Ge Jin; Heather M Ren; Aron E Lukacher
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

Review 9.  A Call to Arms: Quest for a Cryptococcal Vaccine.

Authors:  Marley C Caballero Van Dyke; Floyd L Wormley
Journal:  Trends Microbiol       Date:  2017-11-02       Impact factor: 17.079

10.  Differential In Vitro Cytokine Induction by the Species of Cryptococcus gattii Complex.

Authors:  Patricia F Herkert; Jessica C Dos Santos; Ferry Hagen; Fatima Ribeiro-Dias; Flávio Queiroz-Telles; Mihai G Netea; Jacques F Meis; Leo A B Joosten
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.